Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WST
WST logo

WST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
324.350
Open
323.970
VWAP
322.07
Vol
1.31M
Mkt Cap
22.81B
Low
319.060
Amount
421.23M
EV/EBITDA(TTM)
25.77
Total Shares
70.65M
EV
22.42B
EV/OCF(TTM)
31.34
P/S(TTM)
7.25
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Show More

Events Timeline

(ET)
2026-05-15
13:30:00
West Pharmaceutical Reports Significant Progress in Cyberattack Recovery
select
link
2026-04-23 (ET)
2026-04-23
10:00:00
United Rentals and Others See Notable Gains This Morning
select
2026-04-23
09:10:00
Markets Pull Back as Oil Prices Return Above $100
select
2026-04-23
06:20:00
Company Sees Q2 Revenue of $830M-$850M
select
2026-04-23
06:20:00
Raises FY26 Revenue Outlook to $3.3B-$3.35B
select

News

seekingalpha
7.5
05-21seekingalpha
West Pharmaceutical Services Restores Global Operations After Cyberattack
  • Cyberattack Recovery: West Pharmaceutical Services has fully restored its global manufacturing, supply chain, and commercial operations following a cyberattack earlier this month, demonstrating the company's effectiveness and resilience in crisis management.
  • Core System Restoration: The company stated in a regulatory filing that core enterprise systems and critical processes for manufacturing, receiving, and shipping have been restored at all sites, ensuring business continuity and stability in customer service.
  • Financial Impact Assessment: Based on the latest information from an ongoing investigation, West Pharma does not expect the incident to materially impact its Q2 2026 and full-year financial outlook, reflecting the company's confidence in future performance.
  • Growth Outlook: West Pharmaceutical anticipates revenue between $3.295 billion and $3.35 billion for 2026, with adjusted EPS ranging from $8.40 to $8.75, driven primarily by momentum in high-value product (HVP) components, indicating strong growth potential in the market.
Newsfilter
2.0
05-20Newsfilter
West Pharmaceutical Services Restores Operations Post-Cyberattack
  • Cyberattack Recovery: West Pharmaceutical Services has restored operations across all sites following a cybersecurity attack earlier this month, demonstrating the company's effectiveness and resilience in crisis management.
  • Stable Financial Outlook: The company expects the incident to have no material impact on its 2026 financial outlook, indicating the stability and sustainability of its long-term business.
  • Ongoing Investigation: While the company continues its investigation into the cyberattack, it has not seen any further unauthorized access, suggesting the effectiveness of its cybersecurity measures.
  • Stock Price Bounce: Following the announcement of restored operations, the company's shares rose approximately 2% in after-hours trading, reflecting market confidence in the company's return to normal operations.
Fool
8.5
05-13Fool
Analysis of High Dividend ETF Investment Strategies
  • FDVV ETF Overview: The Fidelity High Dividend ETF has achieved an average annual return of 13.3% since its launch in September 2016, with a current dividend yield of 2.8%, highlighting its appeal in high-dividend investing, although its top four holdings are all tech stocks, which may impact investors' diversification strategies.
  • NOBL ETF Advantages: The ProShares S&P 500 Dividend Aristocrats ETF consists of 69 companies that have paid and increased dividends for at least 25 years, offering a dividend yield of 2.09%, nearly double that of the S&P 500 index, and its P/E ratio of 21 is lower than the S&P 500's 31.9, indicating strong fundamentals.
  • Fee Comparison: FDVV has an expense ratio of 0.15%, while NOBL charges 0.35%, making FDVV more cost-effective, appealing to long-term investors seeking low-cost high-dividend investment options.
  • Investment Recommendation: Although both ETFs have underperformed the S&P 500 index in recent years, FDVV may be more suitable for investors looking to diversify within high-dividend stocks due to its lower fees and higher dividend yield.
seekingalpha
7.0
05-12seekingalpha
West Pharmaceutical Shares Drop Due to Cybersecurity Incident
  • Cybersecurity Incident Impact: West Pharmaceutical disclosed in a regulatory filing that unauthorized access to its data has disrupted global business operations, leading to a second consecutive day of stock price decline, reflecting market concerns over operational stability.
  • Incident Response Measures: The company activated its incident response protocols, taking global systems offline since the initial breach detection on May 8, notifying law enforcement, and engaging external cybersecurity experts, indicating a serious approach to the incident.
  • Business Recovery Progress: While core enterprise systems have been restored, the company is unable to provide a comprehensive timeline for full restoration amid an ongoing investigation, which may negatively impact customer confidence and future revenue.
  • Future Outlook: Despite current challenges, West Pharmaceutical projects 2026 revenue between $3.295 billion and $3.35 billion, with adjusted EPS of $8.40 to $8.75, indicating continued growth momentum driven by high-value product (HVP) components.
Newsfilter
1.0
04-28Newsfilter
West Pharmaceutical Services to Present at Upcoming Investor Conferences
  • Investor Conference Schedule: West Pharmaceutical Services will participate in the Bank of America Global Healthcare Conference on May 12, 2026, and the William Blair Annual Growth Stock Conference on June 2, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's visibility.
  • Webcast Availability: The live webcasts for these events will be accessible in the Investors section of the company's website, with replays available for approximately 90 days post-event, enhancing transparency and fostering interaction with potential investors.
  • Company Performance Overview: West reported net sales of $3.07 billion in fiscal year 2025, demonstrating strong performance in the global injectable solutions market, further solidifying its position as an industry leader.
  • Global Business Footprint: With over 10,000 employees across 50 sites, including 26 manufacturing facilities, West delivers over 41 billion components and devices annually, enabling effective support for drug developers and enhancing its competitive edge in the market.
NASDAQ.COM
8.0
04-27NASDAQ.COM
Analysis of WST Dividend Expectations and Stock Performance
  • Dividend Yield Analysis: WST's estimated annualized dividend yield stands at 0.29%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
  • Stock Price Range: WST's 52-week low is $202.79 per share, with a high of $322.34, and the latest trade at $308.61 indicates that the stock is fluctuating near its high, which may affect investors' buying decisions.
  • ETF Holding Proportion: According to ETF Channel, WST constitutes 4.44% of the Virtus KAR Mid-Cap ETF (KMID), which is trading down about 0.4% on the day, potentially reflecting overall market sentiment towards mid-cap stocks.
  • Intraday Stock Performance: In Monday trading, shares of West Pharmaceutical Services, Inc. are up about 0.7%, indicating a positive short-term market reaction to the company, which may attract more investor attention.
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
Wall Street analysts forecast WST stock price to rise
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Current: 0.000
sliders
Low
285.00
Averages
348.70
High
375.00
Morgan Stanley
Equal Weight
maintain
$315 -> $325
AI Analysis
2026-05-29
New
Reason
Morgan Stanley
Price Target
$315 -> $325
AI Analysis
2026-05-29
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on West Pharmaceutical to $325 from $315 and keeps an Equal Weight rating on the shares after having hosted members of West's management team for investor meetings this week. The firm "sensed strong conviction in both near- and longer-term execution as top-down catalysts play into the company's strengths," the analyst tells investors.
Morgan Stanley
Equal Weight
maintain
$285 -> $315
2026-04-27
Reason
Morgan Stanley
Price Target
$285 -> $315
2026-04-27
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on West Pharmaceutical to $315 from $285 and keeps an Equal Weight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WST
Unlock Now

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 36.36, compared to its 5-year average forward P/E of 42.11. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
42.11
Current PE
36.36
Overvalued PE
49.31
Undervalued PE
34.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
27.46
Current EV/EBITDA
23.21
Overvalued EV/EBITDA
32.66
Undervalued EV/EBITDA
22.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.77
Current PS
6.24
Overvalued PS
9.52
Undervalued PS
6.03

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks to buy short term
Intellectia · 40 candidates
Moving Average Relationship: PriceAboveMA20Week Price Change Pct: $4.00 - $12.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
ELV logo
ELV
Elevance Health Inc
74.87B
QCOM logo
QCOM
Qualcomm Inc
158.82B
VTR logo
VTR
Ventas Inc
39.76B
KDP logo
KDP
Keurig Dr Pepper Inc
39.76B
PKG logo
PKG
Packaging Corp of America
18.95B
BKR logo
BKR
Baker Hughes Co
68.37B
daily top stock picks
Intellectia · 121 candidates
Market Cap: >= 2.00BRegion: USRsi Category: moderate, overboughtPrice Change Pct: >= $3.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
URI logo
URI
United Rentals Inc
50.48B
TXN logo
TXN
Texas Instruments Inc
215.15B
HRI logo
HRI
Herc Holdings Inc
3.60B
MOH logo
MOH
Molina Healthcare Inc
7.97B
STM logo
STM
STMicroelectronics NV
39.87B
WST logo
WST
West Pharmaceutical Services Inc
19.78B
what are the best stocks to buy today
Intellectia · 16 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.65T
PDD logo
PDD
PDD Holdings Inc
150.14B
QCOM logo
QCOM
Qualcomm Inc
149.82B
SMFG logo
SMFG
Sumitomo Mitsui Financial Group, Inc
148.10B
SNY logo
SNY
Sanofi SA
114.04B
CEG logo
CEG
Constellation Energy Corp
106.46B
what is the best stock to invest 6/fev
Intellectia · 31 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
BR logo
BR
Broadridge Financial Solutions Inc
22.70B
AMZN logo
AMZN
Amazon.com Inc
2.39T
NFLX logo
NFLX
Netflix Inc
340.62B
CRM logo
CRM
Salesforce Inc
177.98B
CCI logo
CCI
Crown Castle Inc
37.61B
DELL logo
DELL
Dell Technologies Inc
76.13B
show me stocks strong buy
Intellectia · 16 candidates
Analyst Consensus: Strong BuyEps 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.64T
MSFT logo
MSFT
Microsoft Corp
3.20T
AVGO logo
AVGO
Broadcom Inc
1.57T
ABT logo
ABT
Abbott Laboratories
190.06B
INTU logo
INTU
Intuit Inc
138.84B
BSX logo
BSX
Boston Scientific Corp
138.71B
tell me which stocks are now strong buy
Intellectia · 22 candidates
Market Cap Category: large, megaAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.56T
MSFT logo
MSFT
Microsoft Corp
3.46T
AVGO logo
AVGO
Broadcom Inc
1.52T
MA logo
MA
Mastercard Inc
471.21B
ABT logo
ABT
Abbott Laboratories
186.79B
UBER logo
UBER
Uber Technologies Inc
171.03B
best stocks to invest in 2026 q1
Intellectia · 21 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midAnalyst Consensus: Strong Buy, Moderate BuyReturn On Equity: >= 12.0%Target Price Upside Potential: MoreAbovePriceOne Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
MORN logo
MORN
Morningstar Inc
8.63B
KSPI logo
KSPI
Kaspi.kz AO
14.51B
MANH logo
MANH
Manhattan Associates Inc
10.01B
LOGI logo
LOGI
Logitech International SA
13.49B
TTD logo
TTD
Trade Desk Inc
17.09B
PDD logo
PDD
PDD Holdings Inc
150.37B

Whales Holding WST

J
Jacobs Levy Equity Management Inc
Holding
WST
+16.53%
3M Return
A
Annex Advisory Services, LLC
Holding
WST
+12.91%
3M Return
N
Nan Shan Life Insurance Co., Ltd.
Holding
WST
+11.86%
3M Return
S
Stichting Pensioenfonds ABP
Holding
WST
+11.37%
3M Return
L
LGT Capital Partners Ltd.
Holding
WST
+11.10%
3M Return
M
Moore Capital Management, LP
Holding
WST
+9.47%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 322.81 USD — it has increased 0.31

What is West Pharmaceutical Services Inc (WST)'s business?

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

What is the price predicton of WST Stock?

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

West Pharmaceutical Services Inc revenue for the last quarter amounts to 844.90M USD, increased 21.05

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

West Pharmaceutical Services Inc. EPS for the last quarter amounts to 1.92 USD, increased 56.10

How many employees does West Pharmaceutical Services Inc (WST). have?

West Pharmaceutical Services Inc (WST) has 10800 emplpoyees as of May 31 2026.

What is West Pharmaceutical Services Inc (WST) market cap?

Today WST has the market capitalization of 22.81B USD.